These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21858001)

  • 1. Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa.
    Ncaca LN; Kranzer K; Orrell C
    PLoS One; 2011; 6(8):e23088. PubMed ID: 21858001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.
    Siefried KJ; Mao L; Kerr S; Cysique LA; Gates TM; McAllister J; Maynard A; de Wit J; Carr A;
    PLoS One; 2017; 12(4):e0174613. PubMed ID: 28369066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
    BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Nattey C; Budgell E; van den Berg L; Maskew M; Evans D; Hirasen K; Long LC; Fox MP
    AIDS Patient Care STDS; 2017 May; 31(5):205-212. PubMed ID: 28445088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.
    Marconi VC; Wu B; Hampton J; Ordóñez CE; Johnson BA; Singh D; John S; Gordon M; Hare A; Murphy R; Nachega J; Kuritzkes DR; del Rio C; Sunpath H;
    AIDS Patient Care STDS; 2013 Dec; 27(12):657-68. PubMed ID: 24320011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
    Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
    Fatti G; Shaikh N; Eley B; Grimwood A
    AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
    Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
    AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinant factors for the occurrence of tuberculosis after initiation of antiretroviral treatment among adult patients living with HIV at Dessie Referral Hospital, South Wollo, Northeast Ethiopia, 2020. A case-control study.
    Abdu M; Ali Y; Anteneh S; Yesuf M; Birhanu A; Mohamed S; Hussien A
    PLoS One; 2021; 16(3):e0248490. PubMed ID: 33724992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].
    Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM
    Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line antiretroviral therapy: long-term outcomes in South Africa.
    Murphy RA; Sunpath H; Castilla C; Ebrahim S; Court R; Nguyen H; Kuritzkes D; Marconi VC; Nachega JB
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):158-163. PubMed ID: 22692090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of a Brief, Active Visualisation Intervention to Improve Adherence to Antiretroviral Therapy in Non-adherent Patients in South Africa.
    Jones ASK; Coetzee B; Kagee A; Fernandez J; Cleveland E; Thomas M; Petrie KJ
    AIDS Behav; 2019 Aug; 23(8):2121-2129. PubMed ID: 30259346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.